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Human immunodeficiency virus type 1 (HIV-1) Vpr, a 14-kDa virion-associated protein, plays an important role in the viral
life cycle. Using a panel of truncated HIV-1 LTR-CAT constructs and Vpr expression plasmid, we have identified sequences
from nucleotide 2278 to 2176 in LTR as Vpr-mediated transactivation domain. This region includes the glucocorticoid
response element (GRE) in HIV-1 LTR. Transactivation by Vpr was noted with the HIV-1 LTR reporter constructs containing
CAT or luciferase. A similar effect was also observed with a construct in which the GRE motif was linked to CAT. Studies
involving Vpr mutants identified that helical domains I and III, and amino acid residues at G75 and C76, are responsible for
GRE-mediated LTR transactivation. The transactivation function of Vpr is independent of its cell cycle arrest activity. Further,
viral replication studies indicated that Vpr-mediated increase in viral replication is directly correlated with the ability of Vpr
to transactivate HIV-1 LTR. The results presented here demonstrate that Vpr activates HIV-1 LTR through the host GR
pathway and suggest that an intact GRE in the LTR is critical for Vpr activity. © 2001 Academic Press
Key Words: Vpr; HIV-1 LTR; transactivation; glucocorticoid response element; GRE.
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1INTRODUCTION
Human immunodeficiency virus type-1 (HIV-1) Vpr is a
14-kDa virion-associated nonstructural protein. While Vpr
has been shown to be important for viral replication in
nondividing cells (Connor et al., 1995; Freed et al., 1995;
ubbramanian et al., 1998), a modest effect on viral
eplication in T cell lines was also reported which was
ependent on the multiplicity of virus used for infection
Ogawa et al., 1989). It has been suggested that Vpr
ncreases viral replication in newly infected cells by
ither increasing the host cell permissiveness or by
ctivating viral protein expression (Levy et al., 1995;
owett et al., 1995; Yao et al., 1998). It is likely that the
egulation of transcriptional activation is mediated via a
hain of events occurring between cis elements and
rans-acting factors. The known cis elements for HIV-1
xpression reside in the U3 region of LTR, which include
F-AT, glucocorticoid response element (GRE), NRF, NF-
B, and Sp1 binding sites, TATA box, and the tat-respon-
ive RNA element, TAR (Ghosh, 1992; McAllister et al.,
000; Soudeyns et al., 1993; Verhoef et al., 1999). HIV-1
at is a known transactivator of HIV-1 LTR. Tat-mediated
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334ransactivation has been studied extensively and the
ctivity is mapped to the regions comprising the TATA
ox, Sp-1, and NF-kB binding sites in the LTR (Jones,
997; Kelly et al., 1999; Majello et al., 1998). Vpr has been
reported to exhibit a moderate/weak transactivation ac-
tivity against HIV-1 LTR, as well as other heterologous
promoter elements (Agostini et al., 1996; Cohen et al.,
1990; Wang et al., 1995). However, the molecular basis
for this activity remains unclear.
Vpr, as an intravirion protein, could transactivate HIV-1
LTR and upregulate viral replication prior to the appear-
ance of Tat (Hrimech et al., 1999; Sawaya et al., 2000).
Structure-function studies have indicated that nuclear
localization, virion incorporation, cell cycle arrest, and
transcriptional regulation are mediated by different func-
tional domains of Vpr (Di Marzio et al., 1995; Mahalingam
et al., 1997; Sawaya et al., 1999). Vpr-mediated cell cycle
arrest is linked to an increase in virus production (Goh et
al., 1998; Levy et al., 1995; Yao et al., 1998). In this report,
we have analyzed and mapped the regions required for
the transactivation function of Vpr using different trun-
cated HIV-1 LTR-CAT constructs. These studies have
narrowed down the activity to a region (2278 to 2176)
which contains the GRE sequences (CTTCAAGAACT-
GCTGACAT) in the HIV-1 LTR. To delineate domain(s)
and/or amino acid(s) that are critical for Vpr-mediated
transactivation, we have utilized several Vpr mutants in
conjunction with HIV-1 LTR-Luc and GRE-CAT reporters.
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335Vpr-MEDIATED TRANSACTIVATION OF HIV-1 LTROur results indicate that helical domains I and III, and
amino acid residues at G75 and C76, are involved in
transactivation of HIV-1 LTR. Further, it is also shown that
intravirion Vpr enhances viral gene expression in a man-
ner which is dependent on its ability to transactivate
HIV-1 LTR and virion incorporation. These observations
support an early role for Vpr in HIV-1 infection through
the GR pathway.
RESULTS
Vpr transactivates HIV-1 LTR-directed expression
through GRE
HIV-1 LTR contains many cis-regulatory elements such
as TATA box, NF-kB, Sp1, and GR binding motifs. Using a
panel of HIV-1 LTR-CAT deletion mutant constructs (Fig.
1A), we have mapped the LTR region required for Vpr
function. HeLa cells were cotransfected with Vpr expres-
sion plasmid and LTR-CAT deletion constructs and as-
sayed for CAT activity (Fig. 1B). Cotransfection of pCVpr
and full-length LTR-CAT containing U3, R, and U5 regions
(pBenn-CAT) resulted in a six- to eightfold increase in
CAT activity over the basal level. Similar transactivation
values were observed with HIV-1 LTR mutants 1526
(2278 to 180) and 1527 (2670 to 180). However, co-
transfection of pCVpr with LTR mutants 1520 (248 to
180) (NF-kB sites in reverse orientation), 1525 (248 to
80), 1519 (2103 to 180), 1522 (2117 to 180), and 1523
(2176 to 180) did not have significant CAT activity. Quan-
titative analysis by phosphorimager revealed that the
extent of transactivation is 63 and 66% for HIV-1 LTR
mutants 1526 and 1527, respectively, when compared to
pBenn-CAT by Vpr. These results suggest that se-
quences present between 2278 to 2176 of HIV-1 LTR
are critical for Vpr-mediated transactivation.
Next, we decided to determine whether HIV-1 Tat and
Vpr activate LTR through the same target region or inde-
pendent region(s) in LTR. Cells were cotransfected with
HIV-1 LTR deletion mutants and pSV2Tat and assayed for
CAT activity. Results showed that transactivation by Tat
was noted with mutants 1522, 1523, 1526, and 1527
similar to pBenn-CAT, whereas mutants 1519, 1520, 1521,
and 1525 exhibited low (,50%) activity with respect to
the control (Fig. 1C). These studies indicate that Tat-
mediated activation occurs through the Sp-1, NF-kB bind-
ing motifs, TATA box, and downstream of 11 (TAR stem
loop). On the other hand, Vpr-mediated transactivation
maps to a region corresponding to 2278 to 2176 of
HIV-1 LTR, suggesting that transactivation of HIV-1 LTR
directed expression by Tat and Vpr may involve different
cis-acting elements.
Interestingly, the 2278 to 2176 region of LTR contains
sequences corresponding to the GRE motif. To further
verify that Vpr transactivates HIV-1 LTR through GRE, we
treated the pBenn-CAT and pCVpr cotransfected cells
with different concentrations of GR antagonist mifepris-
Vtone (RU486) and assessed the reporter activity by CAT
ELISA (Fig. 1D). Mifepristone did not alter the basal level
activity in HIV-1 LTR-CAT-transfected cells. However,
treatment of cells with mifepristone inhibited Vpr-medi-
ated LTR transactivation in a dose-dependent manner. A
concentration of 1026 M reduced the Vpr-mediated trans-
ctivation to 13.8 6 1.2 pg/ml compared to 28.1 6 1.9
g/ml in untreated cells, suggesting that Vpr-mediated
IV-1 LTR transactivation is through GRE and this effect
ould be inhibited by GR specific inhibitor mifepristone.
pr domains essential for transactivation function
Structure-function studies have shown that Vpr medi-
tes its pleiotropic effects through different domains. To
dentify the Vpr domain(s) involved in HIV-1 LTR transac-
ivation, HeLa cells were cotransfected with either HIV-1
TR-CAT or HIV-1 LTR-Luc reporter construct and Vpr
utants. The mutants were constructed by overlap PCR
nd characterized for stability of protein, virion incorpo-
ation, and cell cycle arrest. The functional features of
utant Vpr proteins are shown in Table 1. Luciferase
ctivity (RLU units) showed that mutations in helical
omain I, especially at the leucine residues, reduced the
TR-driven luciferase activity significantly compared to
hat of wild-type Vpr (Fig. 2). Partial reduction (40–50%) in
uciferase activity was observed with A30, A59, L67, and
68 Vpr mutants. Interestingly, mutations at L23, G75,
nd C76 (based on the substitutions) impaired the Vpr
ffect below the basal reporter level. Similar results were
lso observed with HIV-1-LTR-CAT (data not shown).
hese results indicate that helical domains I and III, and
he C-terminal domain of Vpr, may contribute to the
ransactivation function.
To confirm whether activation of HIV-1 LTR is through
RE, Vpr mutant expression plasmids were cotrans-
ected with GRE-CAT construct and CAT activity was
uantitated. Substitution of proline to glutamic acid at
esidue 21 and 24 in the helical domain I, leucine to
lanine at position 64, and glycine to alanine at position
5 of Vpr resulted in a significantly lower level of CAT
ctivity (Fig. 3), implicating these domains are important
or GRE-mediated transactivation.
ffect of virion-associated Vpr on HIV-1 replication
To correlate whether Vpr-mediated transactivation of
IV-1 LTR results in viral gene transcription after infec-
ion, we performed viral replication studies using virus
articles containing Vprwt and Vpr mutants in human
eripheral blood mononuclear cells (PBMCs). We used a
ingle round infection system to precisely quantitate the
ffect of virion-associated Vpr on HIV-1 replication. The
irus particles were generated by cotransfection involv-
ng HIV-1 proviral DNA lacking the ability to synthesize
2 2pr and Env (E R ), Vpr, and Env expression plasmids.
Since the Env protein is provided in trans, replication is
336 VANITHARANI ET AL.
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337Vpr-MEDIATED TRANSACTIVATION OF HIV-1 LTRlimited to a single cycle. Equivalent amounts of virus
particles, based on p24 antigen assay, were used as
inoculum to initiate infection of PHA-stimulated PBMCs.
Successful infection of cells by the virus will lead to the
integration of viral DNA into host cellular DNA. Gag and
Gag-pol proteins, directed by the viral RNA in the in-
fected cells, assemble virus particles and are released
into the culture medium. The quantitation of released
virus particles is indicative of the level of viral gene
expression in cells. This system allows a precise quan-
FIG. 1. Mapping the Vpr interacting domains in HIV-1 LTR. (A) HIV-1 L
as follows: pBennCAT (full-length HIV-1 LTR); 1527 (LTR 2670 to 180)
1519 (LTR 2103 to 180); 1525 (LTR 248 to 180); 1520 (LTR 248 to 180
containing the NF-kB sequence in the forward direction. These HIV-1
cotransfected with a panel of HIV-1 LTR-CAT mutants and pCVpr an
Percentage of acetylation for the LTR mutant constructs is indicated. Va
pSV2Tat. Forty-eight hours posttransfection cells were lysed and CAT a
of mifepristone (RU486) on Vpr-mediated HIV-1 LTR transactivation. Cell
T
Characterization of Vpr Mutant
Vpr mutantsa Subcellular localizationb Prot
pcVpr Nuc. membrane
L20A ND
20, 26A Nuc. membrane
21, 24P Cytoplasm . Nuc. membrane
L22A ND
23A ND
26A ND
29P ND
30L Nuc. membrane
30S Cytoplasm . Nuc. membrane
59P Cytoplasm . Nuc. membrane
64S Cytoplasm
67S Nuc. membrane . Cytoplasm
68S Cytoplasm
71C Cytoplasm . Nuc. membrane
H71Y Cytoplasm . Nuc. membrane
G75A Nuc. membrane
C76A Nuc. membrane
C76P Nuc. mem. . Cytoplasm
C76S Nuc. membrane
a Vpr mutants were created by overlap PCR.
b Subcellular localization of Vpr expression was detected by immun
indicates the perinuclear pattern.
c Protein expression was determined by in vitro translation using th
d Incorporation of Vpr into Gag-directed virion-like particles determin
e Cell cycle G2 arrest induced by Vpr mutant molecules was determi
Vpr; 2 indicates cells do not show significant change compared to veas described under Materials and Methods and maintained in the presence
osttransfection and CAT activity was measured using CAT ELISA. All the extitation, unlike the spreading infection assay. To assess
the effect of Vpr in newly infected cells, virus particles
released into the media at the peak of infection were
quantitated. Virus particles containing Vprwt showed
aximal virus replication, whereas mutants H71Y and
76S exhibited reduced levels of replication (Fig. 4).
nterestingly, pNL43 E2R2 complemented with pEnv and
pr mutants E21, 24P, and G75A showed very poor virus
eplication. These results indicate that increase in viral
eplication kinetics by Vpr is directly correlated with the
ant constructs were used to map the Vpr interacting domain. They are
LTR 2278 to 180); 1523 (LTR 2176 to 180); 1522 (LTR 2117 to 180);
ining an NF-kB binding site in reverse direction; 1521 (LTR 248 to 180)
equences are fused to the CAT reporter gene. (B) HeLa cells were
activity was assessed as described under Materials and Methods.
ere derived using pBennCAT as 100%. (C) HIV-1 LTR-CAT mutants and
was measured as described under Materials and Methods. (D) Effect
transfected with pHIV-1 LTR-CAT, alone and in combination with pCVpr
les for Their Biological Activity
ressionc Virion incorporationd Cell cycle arreste
1 1
2 ND
2 1
2 1
1 ND
1 ND
1 ND
ND ND
1 2
1 2
2 2
1 2
1 2
1 2
1 2
1/2 2
1 1
ND 2
ND 2
1 2
scence as described under Materials and Methods. Nuc. membrane
stem. 1 indicates the expression of normal 14 kDa protein.
described under Materials and Methods.
flow cytometry. 1 indicates G2 arrest seen as equivalent as wild-type
nsfected cells.TR mut
; 1526 (
) conta
LTR s
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periments were repeated three times with similar results.
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338 VANITHARANI ET AL.ability to transactivate HIV-1 LTR. Similar results were
observed in multiple experiments using PBMCs isolated
from different normal donors.
DISCUSSION
HIV-1 Vpr, 14-kDa virion-associated protein, functions
during the early and late stages of virus life cycle (Levy,
1998). Vpr exerts its effect by enhancing virus replication
by efficient translocation of the viral preintegration com-
plex in nondividing cells (Heinzinger et al., 1994) and
modulating host cellular transcription machinery to in-
FIG. 2. Mapping of HIV-1 LTR interacting domain in Vpr. HeLa cells (0
nd pHIV-1 LTR-Luc. Forty-eight hours posttransfection, cells were lys
ethods. Transfection efficiency was normalized by b-gal activity and t
erived from duplicate wells. Similar results were observed in multiple
FIG. 3. Mapping the HIV-1 Vpr domains involved in GRE-mediated
pGRE5/CAT construct which contains five consecutive GRE linked ups
lysates were normalized for transfection efficiency by b-gal activity and CA
Numbers denote the fold CAT activation by Vpr and was calculated by phospcrease virus production (Goh et al., 1998; Levy et al.,
995; Rogel et al., 1995; Yao et al., 1998). In this study, we
ave shown that HIV-1 Vpr-induced CAT expression is
ix- to eightfold higher in cells cotransfected with the
IV-LTR-CAT construct than basal level. Using a panel of
runcated LTR-CAT constructs, we have identified the
RE motif as the region essential for Vpr-mediated trans-
ctivation in HIV-1 LTR. Whereas Tat interacting se-
uences corresponding to TATA box, NF-kB, and/or Sp-1
in HIV-1 LTR did not respond to Vpr, these results support
the hypothesis that Vpr and Tat may mediate their trans-
6 cells) were cotransfected with 2 mg of each Vpr expression plasmids
luciferase activity was measured as described under Materials and
al amount of cell lysates was used for luciferase assay. Error bars are
iments.
nsactivation: HeLa cells (0.5 3 106 cells) were cotransfected with a
of the CAT gene and a panel of Vpr mutant expression plasmids. Cell.5 3 10
ed andCAT tra
treamT activity was measured as described in experimental procedures.
horimager. Similar results were observed in multiple experiments.
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339Vpr-MEDIATED TRANSACTIVATION OF HIV-1 LTRactivation effect through distinct regions of HIV-1 LTR. An
earlier study by Wang et al. (1995) showed that Vpr
ransactivates LTR through Sp-1 binding motifs. It should
e pointed out that Wang et al. (1995) used a LTR reporter
onstruct which contained only the NF-kB and Sp-1 bind-
ng sites as the promoter elements. The observed differ-
nces in the data between Wang et al. (1995) and our
aboratory could be due to the differences in the con-
tructs used. Alternatively, it is also likely that Vpr could
ediate transcription from viral LTR through different
is-acting elements.
Structure-function analyses of Vpr have indicated that
uclear localization, cell cycle arrest, and virion incorpo-
ation are mediated by distinct domains of Vpr (Ma-
alingam et al., 1997). Further, it was shown that Vpr’s
unction in cell cycle regulation may be linked to viral
ranscription (Goh et al., 1998; Jowett et al., 1995). Our
analysis of Vpr-mediated transactivation of GRE-CAT re-
vealed that the helical domains I and III and G75 may be
important for Vpr-GR interaction. Disruption of helical
domain I by the substitution of proline for glutamic acid
(E21, 24P) affects the GRE-mediated transactivation.
Such an effect could result from a number of scenarios,
as follows: (i) mutational changes in residues corre-
sponding to the helical domain may alter the stability of
the protein; (ii) specific residues and/or domains may
participate in the interaction of Vpr with the candidate
cellular protein; and (iii) specific residues and/or do-
mains may participate in oligomerization which may be
essential for Vpr function. Helical structure has been
shown to participate in protein–protein, protein–nucleic
FIG. 4. Effect of virion-associated Vpr on virus replication during early
infection: Ficoll–Hypaque fractionated normal human PBMCs (5 3 106)
were stimulated with PHA (5 mg/ml) and infected with Vpr and Env
rans-complemented pNL43 R2E2 pseudoviruses as described under
aterials and Methods. Cell-free supernatants were collected at 24 h
nterval postinfection and assayed for the release of p24 antigen in the
edium. Increase in virus production at peak level is shown for the Vpr
utants. These experiments were repeated using PBMCs from differ-
nt seronegative donors and similar results were observed.acid, and protein–lipid interactions (Tacke et al., 1993;
Mahalingam et al., 1995a,b). By introducing the changesin the first helical domain, it is conceivable that the
affinity of GRE–complex interaction with Vpr may be
disturbed. Amino acids 64–68 contain the signature motif
LXXLL, which is a consensus motif for nuclear receptor
binding (Heery et al., 1997). The low level of GRE-CAT
transactivation by Vpr mutant L67S and L68S may be due
to the inability of these mutants to bind nuclear receptor.
Earlier studies have shown that Vpr provided either in
trans or in cis increased virus replication in primary cells
nd established T cell lines (Goh et al., 1998; Hrimech et
l., 1999; Jowett et al., 1995). Though it is very well
stablished that Tat regulates HIV-1 transcription, the
resence of Vpr along with Tat could increase virus
eplication by different mechanism(s). Upon infection of
arget cells, virion-associated molecules could activate
iral gene expression by recruiting the host cellular tran-
cription machinery to LTR before the appearance of Tat.
n addition, Vpr may induce viral transcription by activat-
ng different cis-acting elements in HIV-1 LTR along with
at, possibly in an additive and/or synergistic manner. To
orrelate LTR transactivation to HIV-1 virus replication,
e have compared the effect of Vpr mutants using a
ingle round infection assay. As expected, Vprwt in-
creased LTR transactivation and enhanced virus replica-
tion, suggesting that Vpr may play an important role in
virus replication through the GRE-mediated pathway. On
the other hand, Vpr mutants showed reduced levels of
virus replication. As these experiments address the func-
tion of virion-associated Vpr, the virion incorporation fea-
ture of mutant Vpr is critical. While Vpr mutant E21, 24P
showed a reduced level of virion incorporation, other
mutants retained a virion incorporation phenotype.
These results suggest that helical domain I and G75 may
be critical for Vpr to interact with GR complex to trans-
activate HIV-1 LTR, and the Vpr-mediated transcriptional
activity depends on its virion incorporation function. Fur-
thermore, the presence of Vpr in the virus particle may
support the viral transcription before de novo synthesis.
The localization of Vpr was found to be important for
Vpr-mediated viral replication (Popov et al., 1998; Sub-
bramanian et al., 1998). However, it is not clear whether
the nuclear localization of Vpr is necessary for GR-path-
way regulation. There is growing evidence for a role for
GR pathway in HIV-1 Vpr biology. Rafaeli et al. (1995)
reported that Vpr is present in the activated GR transcrip-
tion complex and induces GR-mediated HIV-1 LTR trans-
activation. Vpr/GR-mediated transactivation could be in-
hibited by the glucocorticoid antagonist mifepristone. It
has been shown that Vpr inhibited NF-kB activity through
a GR-dependent pathway and this effect could be re-
versed by mifepristone (Ayyavoo et al., 1997). Recently,
Kino et al. (1999) and Sherman et al. (2000) reported that
Vpr is a coactivator of the human glucocorticoid receptor,
as it increased transcription of a glucocorticoid respon-
sive reporter construct. The current study maps the Vpr
transcriptional target site (2278 to 2176) in the HIV-1
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340 VANITHARANI ET AL.LTR, which includes the GRE motif. In agreement with the
LTR activation data, Vpr could increase viral replication
in a similar manner. Taken together, these studies sup-
port the concept that Vpr interacts with the host GR
pathway to mediate HIV-1 LTR transactivation.
Based on our findings, we suggest that Vpr may trans-
activate viral replication through GRE. This supports the
finding that Vpr, as a virion-associated molecule, could
activate LTR-directed expression before Tat becomes
involved in the activation of viral transcription. In addi-
tion, Tat and Vpr could transactivate LTR-directed ex-
pression in an additive manner. Collectively, these data
provide additional clues to Vpr function as it relates to
HIV-1 life cycle and pathogenesis. Inhibitors of this spe-
cific pathway would be of value as antiviral therapeutics
targeted toward this novel accessory gene product.
MATERIALS AND METHODS
Cells
HeLa cells were obtained from ATCC and grown in
DMEM supplemented with 10% FCS, 1% glutamine, and
1% penicillin–streptomycin. 239T cells were obtained
from Dr. Gupta, University of Pittsburgh. Blood from HIV-
1-negative healthy donors was used to isolate PBMCs by
Ficoll–Hypaque (Pharmacia, Piscataway, NJ) gradient
centrifugation. Purified PBMCs were resuspended in
RPMI 1640 supplemented with 10% heat-inactivated FCS,
stimulated with phytohemagglutinin (PHA) (5 mg/ml) for 2
ays, and cultured in IL-2 (5 U/ml)-containing medium.
lasmids
pBennCAT, HIV-1 LTR-CAT constructs were obtained
rom Dr. M. Martin and Dr. Steven Josephs through the
IH ARRRP. Proviral constructs pNL43 R2E2 and pEnv
were obtained from NIH ARRRP, contributed by Dr.
Landau. Mutants of HIV-1 vpr were generated using
overlap PCR (Mahalingam et al., 1997) and were cloned
under the control of the CMV promoter in pCDNA3.1
(Invitrogen, San Diego, CA). All the Vpr mutant constructs
were sequenced to verify the integrity of the mutations.
pGRE5/CAT construct was obtained from U.S. Biochemi-
cals (Cleveland, OH).
Protein expression and subcellular localization in
cells
Protein expression was analyzed by in vitro transcrip-
ion and translation followed by immunoprecipitation as
escribed (Mahalingam et al., 1997). To determine the
ubcellular localization of Vpr mutant molecules in cells,
ndirect immunofluorescence was performed using Vpr-
pecific antiserum as described before (Mahalingam et
l., 1997). Protein stability and virion incorporation anal-
ses were determined as described (Mahalingam et al.,
995b).
w
sransfection
HeLa cells were transfected with different reporter
onstructs in the presence and absence of Vpr mutants
sing DOTAP (Boehringer Mannheim, WI). Forty-eight
ours posttransfection cells were lysed in 100 ml 0.25 M
Tris, pH 7.8 and freeze-thawed using an ethanol–dry ice
bath. Lysates were spun at 12,000 g for 5 min and the
samples were stored at 280°C until they were used. To
measure the effect of mifepristone, cells were main-
tained in the medium containing mifepristone at a con-
centration of 1026 M. Transfection efficiency was normal-
ized by transfecting with CMV-b-gal plasmid and mea-
suring the b-gal activity (Promega, Madison, WI).
AT assay
The levels of CAT activity were measured following
pecific incorporation of [14C]chloramphenicol and de-
tected by autoradiography (Gorman et al., 1982). Briefly,
the CAT reaction was performed using 5 ml [14C]chlor-
amphenicol (40–50 mCi/mmol), 25 mM Tris, pH 7.8, 4 mM
acetyl CoA (Pharmacia), and the cell lysate containing 10
mg proteins were incubated at 37°C for 1 h and subse-
quently extracted with ethyl acetate. Samples were re-
suspended in 20 ml ethyl acetate, spotted on silica gel
LC plates (Whatman), and developed in chloroform:
ethanol (95:5) ascending buffer. Gels were air dried
nd exposed to Kodak X-AR film overnight at room tem-
erature and visualized on a phosphorimager (Molecular
ynamics). CAT activity was quantitated using Image-
uant software.
uciferase assay
HeLa cells (5 3 105) were cotransfected with 5 mg
pCVpr mutants and pHIV-LTR-Luc using DOTAP (Boehr-
inger Mannheim) as per the manufacturer’s recommen-
dation. Two days posttransfection, cells were washed
with 13 PBS and lysed in 500 ml lysis buffer. Lysates
ere spun at 12,000 g for 5 min and the samples were
tored at 280°C until they were used to measure the
uciferase activity (Promega). Transfection efficiency was
ormalized by transfecting with CMV-b-gal plasmid and
measuring the b-gal activity (Promega).
Single round infection assay
To assess the effect of Vpr as a virion-associated
molecule, we have used pseudotyped viruses containing
Vprwt or Vpr mutant molecules. Single-round infection
ssay was used to study the effect of different Vpr mu-
ants on HIV-1 replication. Pseudotype viruses were pro-
uced by cotransfecting 293T cells with proviral DNA
NL43 R2E2 with pEnv and Vpr expression plasmids.
eventy-two hours posttransfection, culture supernatant
as collected and assayed for virus production by mea-
uring the p24 antigen released into the medium. PBMCs
GG
G
H
H
H
J
J
K
K
L
L
M
M
M
M
M
O
P
R
R
R
S
S
S
S
341Vpr-MEDIATED TRANSACTIVATION OF HIV-1 LTR(5 3 106) were infected with 10 ng p24 antigen-equivalent
viruses for 4 h, washed thoroughly with RPMI medium,
and resuspended in appropriate growth medium. Super-
natant was collected at 24 h intervals to measure the p24
antigen (Coulter, Hialeah, FL) released into the medium
to monitor virus replication.
ACKNOWLEDGMENTS
We thank Dr. Reinhart, University of Pittsburgh for review and com-
ments and Salim Saba for technical assistance. HIV-1 LTR-CAT con-
structs were obtained through the AIDS Research and Reference Re-
agent Program, Division of AIDS, NIAID from Dr. Steven Josephs and
Dr. M. Martin. This work was supported by grants from NIH to A.S.,
D.B.W., and V.A.
REFERENCES
Agostini, I., Navarro, J. M., Rey, F., Bouhamdan, M., Spire, B., Vigne, R.,
and Sire, J. (1996). The human immunodeficiency virus type 1 Vpr
transactivator: Cooperation with promoter-bound activator domains
and binding to TFIIB. J. Mol. Biol. 261, 599–606.
Ayyavoo, V., Mahboubi, A., Mahalingam, S., Ramalingam, R., Kudchod-
kar, S., Williams, W. V., Green, D. R., and Weiner, D. B. (1997). HIV-1
Vpr suppresses immune activation and apoptosis through regulation
of nuclear factor kB. Nat. Med. 3, 1117–1123.
Cohen, E. A., Terwillger, E. F., Jalnoos, Y., Proulx, J., Sodroski, J. G., and
Haseltine, W. A. (1990). Identification of HIV-1 Vpr product and func-
tion. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 3, 11–18.
Connor R. I., Chen, B. K., Choe, S., and Landau, N. R. (1995). Vpr is
required for efficient replication of human immunodeficiency virus
type-1 in mononuclear phagocytes. Virology 206, 935–944.
Di Marzio, P., Choe, S., Ebright, M., Knoblauch, R., and Landau, N. R.
(1995). Mutational analysis of cell cycle arrest, nuclear localization
and virion packaging of human immunodeficiency virus type 1 Vpr.
J. Virol. 69, 7909–7916.
Freed, E. O., Englund, G., and Martin, M. A. (1995). Role of the basic
domain of human immunodeficiency virus type 1 matrix in macro-
phage infection. J. Virol. 69, 3949–3954.
hosh, D. (1992). Glucocorticoid receptor-binding site in the human
immunodeficiency virus long terminal repeat. J. Virol. 66, 586–590.
oh, W. C., Rogel, M. E., Kinsey, C. M., Michael, S. F., Fultz, P. N., Nowak,
M. A., Hahn, B. H., and Emerman, M. (1998). HIV-1 Vpr increases viral
expression by manipulation of the cell cycle: A mechanism for
selection of Vpr in vivo. Nat. Med. 4, 65–71.
orman, C., Moffat, L. F., and Howard, B. H. (1982). Recombinant
genomes which express chloramphenicol acetyltransferase in mam-
malian cells. Mol. Cell. Biol. 2, 1044–1051.
eery, D. M., Kalkhoven, E., Hoare, S., and Parker, M. G. (1997). A
signature motif in transcriptional co-activators mediates binding to
nuclear receptors. Nature 387, 733–736.
einzinger, N. K., Bukinsky, M. I., Haggerty, S. A., Ragland, A. M.,
Kewalramani, V., Lee, M. A., Gendelman, H. E., Ratner, L., Stevenson,
M., and Emerman, M. (1994). The Vpr protein of human immunode-
ficiency virus type 1 influences nuclear localization of viral nucleic
acids in nondividing host cells. Proc. Natl. Acad. Sci. USA 91, 7311–
7315.
rimech, M., Yao, X. J., Bachand, F., Rougeau, N., and Cohen, E. A.
(1999). Human immunodeficiency virus type 1 (HIV-1) Vpr functions
as an immediate early protein during HIV-1 infection. J. Virol. 73,
4101–4109.
ones, K. A. (1997). Taking a new TAK on tat transactivation. Genes Dev.
11, 2593–2599.owett, J. B., Planelles, V., Poon, B., Shah, N. P., Chen, M. L., and Chen,
I. S. (1995). The human immunodeficiency virus type 1 vpr genearrests infected T cells in the G2 1 M phase of the cell cycle. J. Virol.
69, 6304–6313.
elly, G. D., Morris, C. B., and Offermann, M. K. (1999). Lack of respon-
siveness of a nuclear factor-kappaB-regulated promoter to transac-
tivation by human immunodeficiency virus 1 Tat in HeLa cells. Virol-
ogy 263, 128–138.
ino, T., Gragerov, A., Kopp, J. B., Stauber, R. H., Pavlakis, G. N., and
Chrousos, G. P. (1999). The HIV-1 virion-associated protein vpr is a
coactivator of the human glucocorticoid receptor. J. Exp. Med. 189,
51–61.
evy, D. N., Rafaeli, Y., and Weiner, D. B. (1995). Extracellular Vpr protein
increases cellular permissiveness of human immunedeficiency virus
replication and reactivates viral latency. J. Virol. 69, 1243–1252.
evy J. A. (1998). “HIV and the Pathogenesis of AIDS.” ASM Press,
Washington, D.C.
ahalingam, S., Collman, R. G., Patel, M., Monken, C. E., and Sriniva-
san, A. (1995a). Functional analysis of HIV 1 Vpr: Identification of
determinants essential for subcellular localization. Virology 212, 331–
339.
ahalingam, S., Khan, S. A., Jabbar, M. A., Monken, C. E., Collman, R.,
and Srinivasan A. (1995b). Mutagenesis of the putative alpha helical
domain of the Vpr protein of human immunodeficiency virus type 1:
Effect on stability and virion incorporation. Proc. Natl. Acad. Sci. USA
92, 3794–3798.
ahalingam, S., Ayyavoo, V., Patel, M., Kieber-Emmons, T., and Weiner,
D. B. (1997). Nuclear import, virion incorporation, and cell cycle
arrest/differentiation are mediated by distinct functional domains of
human immunodeficiency virus type 1 Vpr. J. Virol. 71, 6339–6347.
ajello, B., Napolitano, G., and Lania, L. (1998). Recruitment of the
TATA-binding protein to the HIV-1 promoter is a limiting step for Tat
transactivation. AIDS 12, 1957–1964.
cAllister, J. J., Phillips, D., Millhouse, S., Conner, J., Hogan, T., Ross,
H. L., and Wigdahl, B. (2000). Analysis of the HIV-1 LTR NF-kappaB-
proximal Sp site III: Evidence for cell type-specific gene regulation
and viral replication. Virology 274, 262–277.
gawa, K., Shibata, R., Kiyomasu, T., Higuchi, I., Kishida, Y., Ishimoto, A.,
and Adachi, A. (1989). Mutational analysis of the human immunode-
ficiency virus vpr open reading frame. J. Virol. 63, 4110–4114.
opov, S., Rexach, M., Zybarth, C., Reiling, N., Lee, M., Ratner, L., Lane,
C. M., Moore, M. S., Blobel, G., and Bukrinsky, M. (1998). Viral protein
R regulates nuclear import of the HIV-1 pre-integration complex.
EMBO J. 17, 909–917.
afaeli, Y., Levy, D. N., and Weiner, D. B. (1995). The glucocoticoid
receptor type II complex is a target of the HIV-1 Vpr gene product.
Proc. Natl. Acad. Sci. USA 92, 3621–3625.
ogel, M. E., Wu, L. I., and Emerman, M. (1995). The human immuno-
deficiency virus type 1 vpr gene prevents cell proliferation during
chronic infection. J. Virol. 69, 882–888.
osen, C. A., Sodroski, J. G., and Haseltine, W. A. (1985). The location of
cis-acting regulatory sequences in the human T cell lymphotropic
virus type III (HTLV-III/LAV) long terminal repeat. Cell 41, 813–823.
awaya, B. E., Khalili, K., Gordon, J., Taube, R., and Amini, S. (2000).
Cooperative interaction between HIV-1 regulatory proteins Tat and
Vpr modulates transcription of the viral genome. J. Biol. Chem. 275,
35209–35214.
awaya, B. E., Khalili, K., Rappaport, J., Serio, D., Chen, W., Srinivasan,
A., and Amini, S. (1999). Suppression of HIV-1 transcription and
replication by a Vpr mutant. Gene Ther. 6, 947–950.
herman, M. P., De Noronha, C. M. C., Pearce, D., and Greene, W. C.
(2000). Human immunodeficiency virus type 1 vpr contains two
leucine rich helices that mediate glucocorticoid receptor coactiva-
tion independently of its effects on cell cycle arrest. J. Virol. 74,
8159–8165.
oudeyns, H., Geleziunas, R., Shyamala, G., Hiscott, J., and Wainberg,
M. A. (1993). Identification of a novel glucocorticoid response ele-
ment within the genome of the human immunodeficiency virus type
1. Virology 194, 758–768.
342 VANITHARANI ET AL.Subbramanian, R. A., Kessous-Elbaz, A., Lodge, R., Forget, J., Yao, X. J.,
Bergeron, D., and Cohen, E. A. (1998). Human immunodeficiency
virus type 1 Vpr is a positive regulator of viral transcription and
infectivity in primary human macrophages. J. Exp. Med. 187, 1103–
1111.
Tacke, E., Schmitz, J., Prufer, D., and Rohde, W. (1993). Mutational
analysis of the nucleic acid-binding 17 kDa phosphoprotein of potato
leafroll luteovirus identifies an amphipathic alpha-helix as the do-
main for protein/protein interactions. Virology 197, 274–282.
Verhoef, K., Sanders, R. W., Fontaine, V., Kitajima, S., and Berkhout, B.
(1999). Evolution of the human immunodeficiency virus type 1 long
terminal repeat promoter by conversion of an NF-kappaB enhancer
element into a GABP binding site. J. Virol. 73, 1331–1340.Wang, L., Mukherjee, S., Jia, F., Narayan, O., and Zhao, L. J. (1995).
Interaction of virion protein vpr of human immunodeficiency virus
type 1 with cellular transcription factor Sp1 and trans-activation of
viral long terminal repeat. J. Biol. Chem. 270, 25564–25569.
Yao, X. L., Mouland, A. J., Subbramanian, R. A., Forget, J., Rougeau, N.,
Bergeron, D., and Cohen, E. A. (1998). Vpr stimulates viral expression
and induces cell killing in human immunodeficiency virus type-1
infected dividing Jurkat T cells. J. Virol. 72, 4686–4693.
Yao, X., Subbramanian, R. A., Rougeau, N., Boisvert, F., Bergeron, D.,
and Cohen, E. A. (1995). Mutagenic analysis of human immunodefi-
ciency virus type 1 Vpr: Role of a predicted N-terminal alpha-helical
structure in Vpr nuclear localization and virion incorporation. J. Virol.
69, 7032–7044.
